HRCM
CHRS icon

Hawk Ridge Capital Management’s Coherus Oncology CHRS Stock Holding History

Hawk Ridge Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-656,534
Closed -$11.8M – 46
2019
Q4 		$11.8M Buy
+656,534
New +$12.1M 1.92% 22

Other funds holding CHRS

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Hawk Ridge Capital Management's CHRS Position: Q1 2020 in Review

Hawk Ridge Capital Management sold out of Coherus Oncology (CHRS) in Q1 2020, closing a stake of 656,534 shares — an estimated $11.8M sold.

Hawk Ridge Capital Management first reported a position in CHRS in Q4 2019 and held it in 1 quarter. The position peaked at $11.8M in Q4 2019. 186 funds tracked by Wall St. Rank hold CHRS as of Q1 2020.

  • Hawk Ridge Capital Management reported no remaining Coherus Oncology position as of Q1 2020 after selling out during the quarter.
  • Hawk Ridge Capital Management sold 656,534 Coherus Oncology shares in Q1 2020, an estimated $11.8M.
  • Hawk Ridge Capital Management first reported a position in Coherus Oncology in Q4 2019 and held it in 1 quarter.
  • Hawk Ridge Capital Management's Coherus Oncology position peaked at $11.8M in Q4 2019.
  • 186 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2020.

Based on Hawk Ridge Capital Management's 13F filing for Q1 2020, filed 6 May 2020.